ClinicalTrials.gg
CompletedNCT00441727OberonUpdated Jul 16, 2012Results posted

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

A Phase 3 interventional study of Esomeprazole 40 mg and Esomeprazole 20 mg in Gastric Ulcer and Duodenal Ulcer, sponsored by AstraZeneca. Completed at 191 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.

Enrollment
Largest of 11
2,426 · median 400
Started
2007
with 2 others
Phase 3
9 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
10 of 11
AstraZeneca

Among the 11 studies testing esomeprazole in Stomach Ulcer, this one has the largest enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 3rd registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing esomeprazole in Stomach Ulcer as a file.
02

Study summary

The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.

03

Conditions studied

  • Gastric Ulcer
  • Duodenal Ulcer

Keywords

  • Peptic ulcer
  • low-dose ASA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Daily intake of low-dose Aspirin (ASA) - The subject must fulfill at least one of the following (a-e):
  • Aged ≥65 years.
  • Aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s).
  • Aged ≥60 years and naïve to low-dose ASA (ie, treatment started within 1 month prior to randomization).
  • Aged ≥60 years and with stable coronary artery disease.
  • Aged ≥60 years and with complaints of upper gastrointestinal (GI) symptoms that, as judged by the investigator, requires an Esophagogastroduodenoscopy (EGD) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy.

Exclusion criteria

Exclusion Criteria:

  • Peptic ulcer(s) at baseline esophagogastroduodenoscopy (EGD).
  • Reflux esophagitis Los Angeles (LA) classification grade C or D at baseline
  • History of peptic ulcer complications such as bleeding and/or perforation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,426 participants (actual)

Study arms

  • Experimental
    Esomeprazole 40 mg

    Esomeprazole 40 mg

    Drug: Esomeprazole 40 mg

  • Experimental
    Esomeprazole 20 mg

    Esomeprazole 20 mg

    Drug: Esomeprazole 20 mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).

    The occurrence of ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

    Time frame: During 26 weeks

Secondary outcomes

  1. Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.

    The occurrence of gastric ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

    Time frame: During 26 weeks

  2. Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.

    The occurrence of duodenal ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

    Time frame: During 26 weeks

  3. Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.

    RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence.

    Time frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

  4. Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.

    RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence.

    Time frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

  5. Number of Participants With Gastric and/or Duodenal Erosions.

    Time frame: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

07

Results

Posted Feb 13, 2012
Limitations and caveats
Not enough patients had peptic ulcer, gastric ulcer, or duodenal ulcer to report the intended primary endpoint of time to peptic ulcer and two secondary endpoints, time to gastric ulcer and time to duodenal ulcer. Percentage used instead.

Participant flow

The first subject was randomized 22 February 2007 and last subject completed 28 August 2008. Cardiologists, primary care physicians and gastroenterologists were the primary target investigators.

Participant flow — Overall Study
MilestoneEsomeprazole 40Esomeproazole 20Placebo
Started817804805
Completed711686637
Not completed106118168
Withdrew: Protocol violation192832
Withdrew: Adverse event263328
Withdrew: Lack of efficacy7848
Withdrew: Withdrawal by subject403447
Withdrew: Lost to follow-up565
Withdrew: Safety reasons313
Withdrew: Various reason specified685

Outcome measures

PrimaryPercentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).

The occurrence of ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

Time frame:
During 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).
percentage of participantsEsomeprazole 40Esomeproazole 20Placebo
Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).1.3516.58
SecondaryPercentage of Participants Who Experienced the Occurence of Gastric Ulcer.

The occurrence of gastric ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

Time frame:
During 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.
percentage of participantsEsomeprazole 40Esomeproazole 20Placebo
Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.1.10.754.1
SecondaryPercentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.

The occurrence of duodenal ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

Time frame:
During 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.
percentage of participantsEsomeprazole 40Esomeproazole 20Placebo
Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.0.240.252.73
SecondaryNumber of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence.

Time frame:
RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
Reported as:
Number · participants
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.
participantsEsomeprazole 40 mgEsomeprazole 20 mgPlacbo
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.591577504
SecondaryNumber of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence.

Time frame:
RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
Reported as:
Number · participants
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.
participantsEsomeprazole 40 mgEsomeproazole 20 mgPlacebo
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.554537451
SecondaryNumber of Participants With Gastric and/or Duodenal Erosions.
Time frame:
The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
Reported as:
Number · participants
Number of Participants With Gastric and/or Duodenal Erosions.
participantsEsomeprazole 40Esomeproazole 20Placebo
Number of Participants With Gastric and/or Duodenal Erosions.214213380

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 40———
Esomeproazole 20———
Placebo———
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventEsomeprazole 40Esomeproazole 20Placebo
Cardiac ArrestCardiac disorders0/8142/7991/801
Cerebrovascular AccidentNervous system disorders1/8142/7990/801
Transient Ischaemic AttackNervous system disorders0/8142/7990/801
Angina PectorisCardiac disorders2/8140/7991/801
Angina UnstableCardiac disorders2/8140/7990/801
Coronary Artery DiseaseCardiac disorders2/8141/7991/801
Inguinal HerniaGastrointestinal disorders2/8140/7991/801
Pancreatitis AcuteGastrointestinal disorders2/8141/7990/801
Acute Coronary SyndromeCardiac disorders0/8141/7990/801
Atrial FibrillationCardiac disorders0/8141/7991/801
Most frequent other events
Most frequent other events
EventEsomeprazole 40Esomeproazole 20Placebo
DiarrhoeaGastrointestinal disorders21/81426/79918/801
BronchitisRespiratory, thoracic and mediastinal disorders11/81416/79913/801

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Esomeprazole 40Esomeproazole 20PlaceboTotal
<=18 years0000
Between 18 and 65 years240246260746
>=65 years5775585451680
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 40Esomeproazole 20PlaceboTotal
Female3803754021157
Male4374294031269
08

Study locations

191 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Lancaster, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    San Carlos, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Torrington, Connecticut, United States
  • Research Site
    Boynton Beach, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Jupiter, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    New Smyrna Beach, Florida, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    Plantation, Florida, United States
  • Research Site
    South Miami, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Zephyrhills, Florida, United States
  • Research Site
    Fulton, Illinois, United States
  • Research Site
    Wichita, Kansas, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Hollywood, Maryland, United States
  • Research Site
    Prince Frederick, Maryland, United States
  • Research Site
    Brockton, Massachusetts, United States
  • Research Site
    Jackson, Mississippi, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Egg Harbor Township, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Great Neck, New York, United States
  • Research Site
    Fayetteville, North Carolina, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    Jacksonville, North Carolina, United States
  • Research Site
    Winston-salem, North Carolina, United States
  • Research Site
    Centerville, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Dayton, Ohio, United States
  • Research Site
    Guthrie, Oklahoma, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Harrisburg, Pennsylvania, United States
  • Research Site
    Cranston, Rhode Island, United States
  • Research Site
    Johnston, Rhode Island, United States
  • Research Site
    Anderson, South Carolina, United States
  • Research Site
    Simpsonville, South Carolina, United States
  • Research Site
    Knoxville, Tennessee, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Ogden, Utah, United States
  • Research Site
    Burke, Virginia, United States
  • Research Site
    Chesapeake, Virginia, United States
  • Research Site
    Christiansburg, Virginia, United States
  • Research Site
    Norfolk, Virginia, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Buenos Aires, Buenos Aires- Argentina, Argentina
  • Research Site
    Capital Federal, Buenos Aires, Argentina
  • Research Site
    Loma Hermosa, Buenos Aires, Argentina
  • Research Site
    Lomas de Zamora, Buenos Aires, Argentina
  • Research Site
    Rosario, Santa Fe, Argentina
  • Research Site
    Mendoza, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    Caboolture, Queensland, Australia
  • Research Site
    Carina Heights, Queensland, Australia
  • Research Site
    Adelaide, South Australia, Australia
  • Research Site
    Ballarat, Victoria, Australia
  • Research Site
    Box Hill, Victoria, Australia
  • Research Site
    Geelong, Victoria, Australia
  • Research Site
    NSW, Australia
  • Research Site
    Chirpan, Bulgaria
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Rousse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Bay Roberts, Newfoundland and Labrador, Canada
  • Research Site
    Carbonear, Newfoundland and Labrador, Canada
  • Research Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • Research Site
    St. John's, Newfoundland and Labrador, Canada
  • Research Site
    Brampton, Ontario, Canada
  • Research Site
    Cambridge, Ontario, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Niagara Falls, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Tillsonburg, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Pointe-claire, Quebec, Canada
  • Research Site
    Laval, Canada
  • Research Site
    Longueuil, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Beroun, Czech Republic
  • Research Site
    Brno, Czech Republic
  • Research Site
    Liberec, Czech Republic
  • Research Site
    Litomerice, Czech Republic
  • Research Site
    Ostrava - Trebovice, Czech Republic
  • Research Site
    Podborany, Czech Republic
  • Research Site
    Poobram, Czech Republic
  • Research Site
    Praha 1, Czech Republic
  • Research Site
    Praha 4 - Sporilov, Czech Republic

Showing the first 100 of 191 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Naucler EC, Svedberg LE, Nagy P. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol. 2013 Mar;61(3):250-7. doi: 10.1097/FJC.0b013e31827cb626. PubMed 23188121 ↗
  • Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802. doi: 10.1136/hrt.2010.217547. Epub 2011 Mar 17. PubMed 21415072 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2007
First posted
Mar 1, 2007
Start
Feb 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Feb 13, 2012
Last update
Jul 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00441727
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 1, 2007
Start date
Feb 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Feb 13, 2012
Last update
Jul 16, 2012

Study contacts

Tore Lind, MD, PhD
study director · AstraZeneca
James Scheiman, MD
principal investigator · University of Michigan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion